Close Menu

23andMe

Women's health, drug monitoring,and the company's 23andMe collaboration led organic growth in diagnostics.

The developers said that their multivariant analysis does a better job than using APOE E4 alone at identifying those at greatest risk of developing Alzheimer's. 

The re-emergence of direct-to-consumer genetic health risk tests has healthcare providers worried once again about their impact and utility.

Following the premarket authorization of 23andMe's tests, the agency may allow other firms to sell similar tests DTC without having to submit them for review.

A week after being hit with a GAO report that called test results from consumer genetics firms "misleading," the big three DTC companies criticized the agency for using "unscientific" methods in its undercover investigation, but welcomed greater regulatory oversight.

Pages